Novo Nordisk, a global healthcare company, agreed to acquire three fill-finish sites from Novo Holdings, a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, for $11bn. "We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future. The acquisition complements the significant investments we are already doing in active pharmaceutical ingredients facilities, and the sites will provide strategic flexibility to our existing supply network," Lars Fruergaard Jørgensen, Novo Nordisk President and CEO.